Literature DB >> 9819201

Three-dimensional structure of AmpC beta-lactamase from Escherichia coli bound to a transition-state analogue: possible implications for the oxyanion hypothesis and for inhibitor design.

K C Usher1, L C Blaszczak, G S Weston, B K Shoichet, S J Remington.   

Abstract

The structures of AmpC beta-lactamase from Escherichia coli, alone and in complex with a transition-state analogue, have been determined by X-ray crystallography. The native enzyme was determined to 2.0 A resolution, and the structure with the transition-state analogue m-aminophenylboronic acid was determined to 2.3 A resolution. The structure of AmpC from E. coli resembles those previously determined for the class C enzymes from Enterobacter cloacae and Citrobacter freundii. The transition-state analogue, m-aminophenylboronic acid, makes several interactions with AmpC that were unexpected. Perhaps most surprisingly, the putative "oxyanion" of the boronic acid forms what appears to be a hydrogen bond with the backbone carbonyl oxygen of Ala318, suggesting that this atom is protonated. Although this interaction has not previously been discussed, a carbonyl oxygen contact with the putative oxyanion or ligand carbonyl oxygen appears in most complexes involving a beta-lactam recognizing enzyme. These observations may suggest that the high-energy intermediate for amide hydrolysis by beta-lactamases and related enzymes involves a hydroxyl and not an oxyanion, although the oxyanion form certainly cannot be discounted. The involvement of the main-chain carbonyl in ligand and transition-state recognition is a distinguishing feature between serine beta-lactamases and serine proteases, to which they are often compared. AmpC may use the interaction between the carbonyl of Ala318 and the carbonyl of the acylated enzyme to destabilize the ground-state intermediate, this destabilization energy might be relieved in the transition state by a hydroxyl hydrogen bond. The structure of the m-aminophenylboronic acid adduct also suggests several ways to improve the affinity of this class of inhibitor and points to the existence of several unusual binding-site-like features in the region of the AmpC catalytic site.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9819201     DOI: 10.1021/bi981210f

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  34 in total

1.  Structural basis for imipenem inhibition of class C beta-lactamases.

Authors:  Beth M Beadle; Brian K Shoichet
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

2.  Structural study of phenyl boronic acid derivatives as AmpC beta-lactamase inhibitors.

Authors:  Donatella Tondi; Samuele Calò; Brian K Shoichet; Maria Paola Costi
Journal:  Bioorg Med Chem Lett       Date:  2010-04-09       Impact factor: 2.823

3.  Identification of residues critical for catalysis in a class C beta-lactamase by combinatorial scanning mutagenesis.

Authors:  Shalom D Goldberg; William Iannuccilli; Tuan Nguyen; Jingyue Ju; Virginia W Cornish
Journal:  Protein Sci       Date:  2003-08       Impact factor: 6.725

4.  The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.

Authors:  R A Powers; J Blázquez; G S Weston; M I Morosini; F Baquero; B K Shoichet
Journal:  Protein Sci       Date:  1999-11       Impact factor: 6.725

Review 5.  The versatility of boron in biological target engagement.

Authors:  Diego B Diaz; Andrei K Yudin
Journal:  Nat Chem       Date:  2017-07-25       Impact factor: 24.427

6.  Label-free fiber optic optrode for the detection of class C β-lactamases expressed by drug resistant bacteria.

Authors:  Simona Zuppolini; Giuseppe Quero; Marco Consales; Laura Diodato; Patrizio Vaiano; Alberto Venturelli; Matteo Santucci; Francesca Spyrakis; Maria P Costi; Michele Giordano; Antonello Cutolo; Andrea Cusano; Anna Borriello
Journal:  Biomed Opt Express       Date:  2017-10-23       Impact factor: 3.732

7.  Structure-based optimization of cephalothin-analogue boronic acids as beta-lactamase inhibitors.

Authors:  Stefania Morandi; Federica Morandi; Emilia Caselli; Brian K Shoichet; Fabio Prati
Journal:  Bioorg Med Chem       Date:  2007-11-07       Impact factor: 3.641

8.  Characterization of a novel plasmid-mediated cephalosporinase (CMY-9) and its genetic environment in an Escherichia coli clinical isolate.

Authors:  Yohei Doi; Naohiro Shibata; Keigo Shibayama; Kazunari Kamachi; Hiroshi Kurokawa; Keiko Yokoyama; Tetsuya Yagi; Yoshichika Arakawa
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  AmpC beta-lactamase in an Escherichia coli clinical isolate confers resistance to expanded-spectrum cephalosporins.

Authors:  Hedi Mammeri; Hasan Nazic; Thierry Naas; Laurent Poirel; Sophie Léotard; Patrice Nordmann
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

10.  Inhibition of the class C beta-lactamase from Acinetobacter spp.: insights into effective inhibitor design.

Authors:  Sarah M Drawz; Maja Babic; Christopher R Bethel; Magda Taracila; Anne M Distler; Claudia Ori; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2010-01-19       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.